SMAD1 antisense RNA 2 (SMAD1-AS2)

SMAD1 antisense RNA 2 (SMAD1-AS2) is a long noncoding RNA transcribed from the strand opposite to the SMAD1 gene locus. As a natural antisense transcript, SMAD1-AS2 likely participates in the post-transcriptional and/or epigenetic regulation of SMAD1 gene expression, potentially by RNA:RNA interactions, chromatin remodeling, or interfering with microRNA function. Such antisense RNAs have emerging roles in fine-tuning key regulatory genes involved in processes such as development, differentiation, and disease. While antisense RNAs for related signaling genes (e.g., ZEB2-AS1, BACE1-AS) have demonstrated mechanistic importance in regulating gene expression and contributing to disease phenotypes, specific functional or disease roles for SMAD1-AS2 remain to be characterized in detail. There are currently no approved drugs targeting SMAD1-AS2. Antisense lncRNAs (like SMAD1-AS2) are an expanding field; other NATs regulate gene expression by diverse mechanisms, including recruiting chromatin modifiers, sponging miRNAs, and altering splicing. SMAD1 (the protein-coding gene paired with SMAD1-AS2) is a key mediator in the BMP branch of the TGF-β signaling pathway, implicating this locus in processes like development, cell proliferation, and cancer. However, SMAD1-AS2 itself is not a conventional "target" in drug discovery, although it may become one if future research reveals a functional role. SMAD1-AS2 is a long noncoding RNA classified as a natural antisense transcript (NAT), involved in chromatin and post-transcriptional gene regulation, but is not currently recognized as a direct therapeutic target such as a receptor, enzyme, or transporter. Its biological and disease associations are inferred from its family and locus but require further definition specific to SMAD1-AS2.

Other names

SMAD1-AS2